辛伐他汀对不稳定型心绞痛的抗心肌缺血作用

Anti-myocardial Ischemia Function of Simvastatin on Patients with Unstable Angina Pectoris

要目的要探讨辛伐他汀对不稳定型心绞痛(UA)患者的抗心肌缺血作用。方法要105例冠心病随机分成两组:对照组52例用西药常规治疗,治疗组53例在采用对照组治疗方法的基础上加用辛伐他汀片20mg,口服,1次/d。两组均治疗8周,观察24h动态心电图,于治疗前、后分别检测心肌缺血总负荷(TIB)和记录临床缺血相关事件,并检测治疗前后高敏CRP(Hs-CRP)、TC、TG和LDL-C的变化。结果要治疗后治疗组与对照组相比,TIB、Hs-CRP、TC、TG和LDL-C均显著低于对照组(P<0.05),缺血相关事件发生率明显下降(P<0.05)。结论要辛伐他汀能有效地降低血脂及Hs-CRP,具有较明显的抗心肌缺血作用。

Objective To explore Simvastatin＇s anti-myocardial ischemia function on the patients with unstable angina pectoris. Methods Divide 105 patients with unstable angina pectoris into two groups： the group for comparison（52 patients, with normal remedy） and the group for remedy（53 patients, with Simvastatin 20mg/ d）. The total period of treatment was 8 weeks. Record the clinic myocardial ischemia events. The changes of the total ischemia burden （TIB） which was recorded from the 24h-holter and the high-sensitivity C-responsibility protein（Hs-CRP）, the total cholesterol（TC）, the triglyceride（TG）, and the low density lipoprotein cholesterol（LDLC） levels were observed before and after treatment. Results The concentrations of Hs-CRP, TC, TG and LDL-C in the group for remedy after the treatment were significantly lower than in the group for comparison. In addition, the myocardial ischemia events in the group for remedy were obviously lower than the group for comparison （P〈0.05）. Conclusion Simvastatin can effectively decrease Hs-CRP and lipidemia. It has obvious anti-myocardial ischemia function on the patients with unstable angina pectoris.